Skip to content

EBIT at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$73.23M+15.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$169M-18.2%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Corcept Therapeutics logo
Corcept TherapeuticsCORT
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Calculated from Crinetics Pharmaceuticals’s reported figures.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's EBIT?
Crinetics Pharmaceuticals (CRNX) reported EBIT of -$140.38M in Q1 2026.
How has Crinetics Pharmaceuticals's EBIT changed year-over-year?
Crinetics Pharmaceuticals's EBIT decreased by 26.0% year-over-year, from -$111.41M to -$140.38M.
What is the long-term trend for Crinetics Pharmaceuticals's EBIT?
Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EBIT has grown at a 48.0% compound annual growth rate (CAGR), from -$107.7M to -$516.77M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.